 | N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States. In early 2020, in collaboration with NRC the... 5 KB (289 words) - 11:53, 30 December 2023 |
Research Council of Canada (NRC) to produce a COVID-19 vaccine—VBI-2902. In August VBI received CA$56 million from the Government of Canada to prepare... 4 KB (366 words) - 11:53, 30 December 2023 |
| 2021. "VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines... 98 KB (20,593 words) - 02:58, 8 March 2024 |
DelNS1-2019-nCoV-RBD-OPT GRAd-COV2 ImmunityBio iNCOVACC INNA-051 NDV-HXP-S Vaxart COVID-19 vaccine Virus-like particles ABNCoV2 LYB001 MigVax-101 VBI-2902... 181 KB (23,901 words) - 14:23, 6 January 2024 |